(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 15 September 2005 (15.09.2005)

PCT

(10) International Publication Number WO 2005/085868 A1

- (51) International Patent Classification⁷: G01N 33/68
- (21) International Application Number:

PCT/SE2005/000316

- (22) International Filing Date: 3 March 2005 (03.03.2005)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 0400564-1

5 March 2004 (05.03.2004) SE

- (71) Applicant (for all designated States except US): ASTRAZENECA AB [SE/SE]; S-151 85 Södentälje (SE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LEPISTÖ, Matti [SE/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE). PAWLOWSKI, Krzysztof [PL/SE]; AstraZeneca R & D Lund, S-221 87 Lund (SE).
- (74) Agent: ASTRAZENECA, Global Intellectual Property, S-151 85 Södertälje (SE).

- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR IDENTIFYING COMPOUNDS CAPABLE OF MODULATING THE HYDROLASE ACTIVITY OF CLCA PROTIEN.

(57) Abstract: Methods for identifying compounds capable of modulating the hydrolase activity of a CLCA protein include screening and computer modelling methods. The compounds, including antibodies, may be useful as therapeutic agents to treat a variety of diseases.